Severe malarial anemia (SMA) is a primary cause of morbidity and mortality in immune-naïve infants and young children residing in areas of holoendemic Plasmodium falciparum transmission. Although the immunopathogenesis of SMA is largely undefined, we have previously shown that systemic interleukin-12 (IL-12) production is suppressed during childhood blood-stage malaria. Since IL-10 and tumor necrosis factor alpha (TNF-alpha) are known to decrease IL-12 synthesis in a number of infectious diseases, altered transcriptional regulation of these inflammatory mediators was investigated as a potential mechanism for IL-12 down-regulation. Ingestion of naturally acquired malarial pigment (hemozoin [PfHz]) by monocytes promoted the overproduction of IL-10 and TNF-alpha relative to the production of IL-12, which correlated with an enhanced severity of malarial anemia. Experiments with cultured peripheral blood mononuclear cells (PBMC) and CD14(+) cells from malaria-naïve donors revealed that physiological concentrations of PfHz suppressed IL-12 and augmented IL-10 and TNF-alpha by altering the transcriptional kinetics of IL-12p40, IL-10, and TNF-alpha, respectively. IL-10 neutralizing antibodies, but not TNF-alpha antibodies, restored PfHz-induced suppression of IL-12. Blockade of IL-10 and the addition of recombinant IL-10 to cultured PBMC from children with SMA confirmed that IL-10 was responsible for malaria-induced suppression of IL-12. Taken together, these results demonstrate that PfHz-induced up-regulation of IL-10 is responsible for the suppression of IL-12 during malaria.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1594872PMC
http://dx.doi.org/10.1128/IAI.00843-06DOI Listing

Publication Analysis

Top Keywords

malarial anemia
12
il-10 tnf-alpha
12
suppression il-12
12
il-10
9
severe malarial
8
il-12
8
il-10 responsible
8
tnf-alpha
5
acquisition hemozoin
4
hemozoin monocytes
4

Similar Publications

Background: There are reports of a high prevalence of maternal peripheral and placental malarial parasitaemia (MP) in southeastern Nigeria following the two-dose regimen of sulphadoxine-pyrimethamine (SP) for intermittent preventive treatment (IPT) of malaria in pregnancy.

Objective: To compare the effectiveness of monthly versus two-dose regimens of SP for IPT of malaria in pregnancy in Enugu, south-eastern Nigeria.

Methods: A randomized controlled trial involving antenatal clinic attendees at the University of Nigeria Teaching Hospital (UNTH), Ituku-Ozalla, Enugu, Nigeria.

View Article and Find Full Text PDF

In patients presenting with post-malarial anemia following intravenous artesunate treatment, post-artesunate delayed hemolysis should be considered in the differential diagnosis, even in endemic settings. Close monitoring for signs of delayed hemolysis in patients previously treated with intravenous artesunate for severe malaria, regardless of their malaria exposure history or geographic location is crucial.

View Article and Find Full Text PDF
Article Synopsis
  • Placental malaria (PM) in the Metti Health Centre study showed high prevalence rates: 34.4% for PM, 24.4% for gestational malaria (GM), and significant issues like maternal anemia (41.7%) and low birth weight (27.8%).
  • Key risk factors identified for GM included recent malaria history, lack of indoor residual spraying, and absence of antenatal care, whereas for PM, recent malaria history and lack of antenatal care were highlighted.
  • The study utilized a cross-sectional design with various diagnostic tools to assess the impact of malaria on pregnancy outcomes among parturient women in Southwest Ethiopia.
View Article and Find Full Text PDF

Background: High-grade resistance to sulfadoxine-pyrimethamine in East and Southern Africa has prompted numerous trials evaluating intermittent preventive treatment in pregnancy (IPTp) with dihydroartemisinin-piperaquine as an alternative to sulfadoxine-pyrimethamine.

Methods: We conducted individual participant data meta-analyses of randomised trials comparing IPTp with dihydroartemisinin-piperaquine to sulfadoxine-pyrimethamine on maternal, birth, and infant outcomes. We searched the WHO International Clinical Trials Registry Platform, ClinicalTrials.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!